Convergence Investment Partners’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-37,599
Closed -$2.43M 262
2026
Q1
$2.43M Buy
37,599
+6,748
+22% +$476K 0.4% 78
2025
Q4
$2.08M Buy
30,851
+10,766
+54% +$724K 0.41% 74
2025
Q3
$1.47M Sell
20,085
-7,390
-27% -$491K 0.33% 102
2025
Q2
$1.43M Sell
27,475
-1,064
-4% -$60.5K 0.36% 92
2025
Q1
$1.82M Sell
28,539
-6,174
-18% -$359K 0.5% 57
2024
Q4
$1.66M Buy
34,713
+7,151
+26% +$367K 0.37% 96
2024
Q3
$1.58M Buy
27,562
+1,316
+5% +$75.4K 0.43% 73
2024
Q2
$1.37M Buy
+26,246
New +$1.15M 0.4% 71
2024
Q1
Sell
-7,008
Closed -$259K 255
2023
Q4
$259K Buy
+7,008
New +$264K 0.14% 154
2016
Q1
Sell
-172,134
Closed -$2.98M 364
2015
Q4
$2.98M Sell
172,134
-79,614
-32% -$1.27M 0.33% 109
2015
Q3
$3.38M Buy
+251,748
New +$5.05M 0.39% 91

Other funds holding HALO

Convergence Investment Partners's HALO Position: Q2 2026 in Review

Convergence Investment Partners sold out of Halozyme (HALO) in Q2 2026, closing a stake of 37,599 shares — an estimated $2.43M sold.

Convergence Investment Partners first reported a position in HALO in Q3 2015 and held it in 11 quarters. The position peaked at $3.38M in Q3 2015. 673 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Convergence Investment Partners reported no remaining Halozyme position as of Q2 2026 after selling out during the quarter.
  • Convergence Investment Partners sold 37,599 Halozyme shares in Q2 2026, an estimated $2.43M.
  • Convergence Investment Partners first reported a position in Halozyme in Q3 2015 and held it in 11 quarters.
  • Convergence Investment Partners's Halozyme position peaked at $3.38M in Q3 2015.
  • 673 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Convergence Investment Partners's 13F filing for Q2 2026, filed 31 Jul 2026.